Due to the significant enhancement of CCL2 in the serum and BALF of IPF patients and its critical role in IPF development, further studies are needed to identify new agents that can effectively suppress CCL2, which may provide significant benefits to patients with progressive IPF. Here, CCL2 is linked to idiopathic pulmonary fibrosis.